Research Context
The WOLVERINE STACK is a focused combination of two flagship research compounds — BPC and TB — researched together for synergy in tissue-repair and recovery pathways. Each component is supplied at >99% HPLC purity.
The WOLVERINE STACK is a widely cited stack of research peptides, frequently grouped with the GLOW STACK and KLOW STACK in regenerative research. These compounds form the backbone of many recovery-focused study designs.
A combination of BPC-157 and TB-500 researched together for synergy in tissue-repair and recovery pathways.
WOLVERINE STACK: BPC-157/TB-500 Dual-Peptide Research Complex
The WOLVERINE STACK is a proprietary dual-peptide research formulation combining BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4). This specific 1:1 ratio (40mg each, totaling 80mg) is engineered for research models investigating structural connective tissue repair, musculoskeletal healing, angiogenesis, and anti-fibrotic pathways. The WOLVERINE STACK is widely studied alongside the GLOW STACK (which adds GHK-Cu for dermal/collagen focus) and the KLOW STACK (which adds KPV for mucosal/anti-inflammatory support).
By isolating BPC-157 and TB-500, the WOLVERINE blend provides a highly concentrated, synergistic approach to tissue regeneration. BPC-157 is renowned for its role in tendon, ligament, and gut healing via vascular endothelial growth factor (VEGF) modulation, while TB-500 enhances cellular migration and actin cytoskeleton dynamics.
Together, the two peptides create a powerful model for studying accelerated wound closure and structural tissue repair. Laboratories looking to buy research-grade Wolverine Stack typically source mg-dosed material with batch-specific HPLC verification for tissue repair and recovery investigations.
All components of the WOLVERINE STACK are supplied at ≥99% HPLC purity with batch-matched third-party Certificates of Analysis.
SCYRX offers the Wolverine Stack for sale exclusively to qualified researchers and institutions. The blend is intended for laboratory research purposes only and is not approved for human use.
Individual Component Research Mechanisms
BPC-157 is a stable, 15-amino-acid peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) originally derived from human gastric juice. Research highlights its cytoprotective and regenerative properties, primarily mediated through the upregulation of VEGF receptors, modulation of the nitric oxide (NO) signaling pathway, and promotion of angiogenesis. In musculoskeletal models, BPC-157 has been shown to accelerate the healing of transected tendons, ligaments, and skeletal muscle by stimulating fibroblast proliferation and collagen deposition.
TB-500 is the synthetic version of Thymosin Beta-4, a naturally occurring 43-amino-acid peptide. Its primary mechanism of action involves the sequestration of monomeric G-actin, preventing its polymerization into F-actin. This regulation of the actin cytoskeleton is critical for cell motility and migration. Research demonstrates TB-500 promotes the migration of endothelial cells and keratinocytes to injury sites, stimulates new blood vessel formation (angiogenesis), and downregulates inflammatory cytokines to reduce fibrosis and scar tissue formation during the remodeling phase of wound healing.
WOLVERINE STACK Research Applications
Musculoskeletal and Connective Tissue Repair
The WOLVERINE STACK is frequently selected for research models investigating tendon, ligament, and skeletal muscle repair. The synergistic action of BPC-157's angiogenic support and TB-500's cell migration properties creates an optimal environment for studying the healing of dense connective tissues, which traditionally have poor blood supply and slow recovery rates.
Angiogenesis and Wound Healing
Both peptides independently and synergistically promote neovascularization. Research models utilize this WOLVERINE blend to study accelerated wound closure rates, granulation tissue formation, and re-epithelialization. The combination is particularly valuable in studies examining compromised wound healing, such as in diabetic or ischemic models.
Anti-Fibrotic and Scar Tissue Research
Excessive scar tissue formation (fibrosis) is a major complication in tissue repair. TB-500 has been shown to modulate the expression of matrix metalloproteinases (MMPs) and reduce the deposition of disorganized collagen. Researchers use the WOLVERINE STACK to investigate protocols aimed at promoting functional tissue regeneration with minimal scar tissue, preserving the biomechanical properties of the healed tissue.
WOLVERINE STACK vs. GLOW STACK vs. KLOW STACK: Comparative Analysis
| Feature | WOLVERINE STACK | GLOW STACK | KLOW STACK |
|---|---|---|---|
| Peptide Composition | BPC-157, TB-500 (1:1 ratio) | GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg) | GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg), KPV (10mg) |
| Total Peptide Content | 10mg or 20mg (varies by vial size) | 70mg | 80mg |
| Primary Research Focus | Connective tissue repair, musculoskeletal healing, angiogenesis | Dermal regeneration, ECM remodeling, collagen synthesis | Comprehensive tissue regeneration with mucosal and anti-inflammatory support |
| Key Distinguishing Component | Standard-dose BPC-157 and TB-500 in 1:1 ratio (no GHK-Cu or KPV) | GHK-Cu (copper peptide for collagen/elastin) | KPV (anti-inflammatory tripeptide from α-MSH) |
| Angiogenesis Support | Strong (high-dose BPC-157, TB-500) | Moderate (BPC-157, TB-500) | Moderate (BPC-157, TB-500) |
| Collagen Synthesis | Moderate (via healing cascade) | Strong (GHK-Cu specific) | Strong (GHK-Cu specific) |
| Anti-Inflammatory Pathway | Minimal | Mild (GHK-Cu antioxidant) | Strong (KPV NF-κB inhibition) |
| Mucosal Protection | Moderate (BPC-157) | Mild (BPC-157) | Strong (KPV plus BPC-157) |
| Anti-Fibrotic Effects | Strong (TB-500) | Moderate (TB-500) | Strong (TB-500, KPV) |
Note: WOLVERINE STACK is available in 10mg vials (5mg BPC-157 + 5mg TB-500) or 20mg vials (10mg BPC-157 + 10mg TB-500). Formulation ratios and total peptide content may vary by batch. Always refer to the batch-specific Certificate of Analysis (COA) included with your order for exact composition.
WOLVERINE STACK Chemical Specifications
| Specification | Value |
|---|---|
| Peptide Components | BPC-157, TB-500 |
| BPC-157 CAS Number | 137525-51-0 |
| BPC-157 Molecular Formula | C₆₂H₉₈N₁₆O₁₁ |
| TB-500 CAS Number | 77095-66-2 |
| TB-500 Molecular Formula | C₂₁₂H₃₅₀N₅₆O₇₈S |
| Typical Total Content | 80mg (may vary by batch) |
| Purity | ≥99% by HPLC |
| Form | Lyophilized white powder |
Note: Formulation ratios and purity metrics may vary by batch. Always refer to the batch-specific Certificate of Analysis (COA) included with your order for exact composition and laboratory-verified specifications.
Storage and Stability
Lyophilized WOLVERINE STACK should typically be stored at −20 °C in a tightly sealed container, protected from light and moisture. Under these conditions, it generally remains stable for up to 24 months from the manufacture date.
The lyophilized WOLVERINE blend can typically be shipped at room temperature for short periods (up to two weeks) without significant degradation, though refrigerated shipping is preferred for long-distance transport to ensure maximum stability.
Once reconstituted with bacteriostatic water, the solution should be refrigerated at 2–8 °C and typically used within 28 days. Researchers should avoid repeated freeze-thaw cycles and vigorous shaking to maintain peptide integrity. Unlike GHK-Cu blends, the reconstituted WOLVERINE STACK solution will be clear and colorless.
Research Protocol Considerations
Reconstitution. The WOLVERINE STACK is typically reconstituted with bacteriostatic water. Typical reconstitution volumes range from 1–3 mL depending on the desired concentration for the specific research model. Because this blend contains higher individual amounts of BPC-157 and TB-500 compared to the 3- and 4-peptide stacks, researchers should adjust their dosing calculations accordingly.
Complementary Research. Investigators studying comprehensive musculoskeletal or recovery protocols often research the WOLVERINE STACK alongside compounds like Melanotan II (MT2) for synergistic healing effects, or mitochondrial support compounds like SS-31. Researchers requiring dermal collagen synthesis or mucosal anti-inflammatory pathways typically opt for the GLOW or KLOW stacks, respectively.
Research Dosing Considerations
In preclinical research models, the Wolverine Stack is evaluated in milligram (mg) quantities due to its multi-peptide composition. Administration is most frequently via subcutaneous injection. Researchers typically use reconstitution volumes of 1–3 mL for precise measurement of the lyophilized blend to ensure accurate dosing of each component.
Related Research Peptides
WOLVERINE STACK Research FAQ
Is the Wolverine Stack legal for research purposes?
Yes. The Wolverine Stack sold by SCYRX is intended strictly for in vitro laboratory research and is not for human or veterinary use. All products are sold to licensed researchers and institutions for laboratory research purposes only.
What is the primary mechanism of Wolverine in tissue repair research?
Wolverine is a proprietary blend designed to maximize systemic recovery by combining potent angiogenic and cell-migration peptides. By leveraging the synergistic effects of its components, it aims to accelerate the healing of tendons, ligaments, and muscle tissue in laboratory models.
How does Wolverine differ from using individual peptides like BPC-157?
While BPC-157 is excellent for localized gut and tendon health, Wolverine provides a broader 'whole-body' regenerative effect. The inclusion of TB-500 enhances cell migration and reduces fibrosis, creating a more comprehensive protocol for studying complex tissue injuries.
Why is Wolverine frequently studied in sports medicine research?
Wolverine targets the multiple phases of the healing cascade simultaneously. It is extensively researched for its potential to improve collagen organization, reduce inflammation, and restore functional mobility in models of acute and chronic musculoskeletal injury.
Does Wolverine cause significant side effects in research models?
As a blend of well-tolerated endogenous peptides, Wolverine is generally considered safe in research literature. The most commonly reported effects are mild injection site reactions. Due to its balanced formulation, it does not typically cause hormonal shifts.
Can Wolverine be stacked with other research compounds?
Yes. Researchers often combine Wolverine with growth hormone secretagogues like Ipamorelin to study holistic recovery. Each should be reconstituted and administered separately to ensure stability.
Scientific References and Citations
- Sikiric P, Seiwerth S, Rucman R, et al. The relationship between the cytoprotective action of BPC 157 and nitric oxide. J Physiol Paris. 2007;100(5-6):292-299. doi:10.1016/j.jphysparis.2007.03.003
- Seiwerth S, Rucman R, Vukojevic V, et al. BPC 157 and blood vessels: a review of experimental evidence. Drug Dev Ind Pharm. 2018;44(11):1763-1770. doi:10.1080/03639045.2018.1497734
- Chang CH, Kuo TF, Lin WC, et al. BPC 157 accelerates the healing of transected rat Achilles tendon. J Orthop Res. 2010;28(12):1620-1627. doi:10.1002/jor.21192
- Goldstein AM, et al. Thymosin beta 4 promotes cardiac myocyte survival and reduces infarct size after ischemia-reperfusion injury. Ann N Y Acad Sci. 2012;1269:155-163. doi:10.1111/j.1749-6632.2012.06705.x
- Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 and its fragment KTTKS stimulate matrix metalloproteinase expression in human dermal fibroblasts. Ann N Y Acad Sci. 1999;885:422-424. doi:10.1111/j.1749-6632.1999.tb09785.x
- Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2007;84(2):297-304. doi:10.1016/j.exer.2006.09.016
- Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000
- Philp D, Scheremeta B, Sibliss K, et al. Thymosin beta4 promotes matrix metalloproteinase expression during wound repair. J Cell Physiol. 2006;208(1):195-200. doi:10.1002/jcp.20646
- Hocking DC, Sottile J, Langenbach KJ. Stimulation of actin polymerization by a short peptide derived from the actin-binding domain of thymosin beta-4. J Biol Chem. 2001;276(3):1864-1869. doi:10.1074/jbc.M008287200
- Goldstein AL, Hannapel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.003
